Leader in development of high-quality recombinant antibodies receives grant funding to develop new conversion technique

Branford, Conn. (PRWEB) October 13, 2015

AxioMx Inc., a leader in the development of high-quality recombinant antibodies, today announced that it has received a Phase I Small Business Innovative Research (SBIR) grant (1R43GM112204-01A1). This Phase I award, which will be administered by the National Institute of General Medical Sciences (NIGMS), will fund the development of a technique to rapidly convert single-chain variable fragments (scFvs) to full-length immunoglobulin G (IgG) molecules, the most common form of antibody used in research today.

AxioMx creates custom antibodies by screening a library of more than 10 billion different antibody fragments (scFvs) to identify binders to a target antigen. Although the use of scFvs in this process is simple and efficient, the molecule is in a different format than IgGs found in nature.

“Although some of our customers prefer a scFv as their deliverable, many others request IgGs,” said Chris McLeod, president and CEO of AxioMx. “We are currently quite capable of accommodating this request; however, the funding we have received will support implementing a new method that can convert scFv antibodies into IgG molecules quicker and at lower cost than any other technique available.”

advertisement | advertise on newsday

“The beauty of this method is that it allows bacteria to perform all of the steps that previously required multiple hours of human labor,” said Michael Weiner, Ph.D., chief scientific officer and founder of AxioMx.

About AxioMx Inc.
AxioMx, founded in 2012 and based in Branford, Connecticut, is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics, and proteomics organizations. AxioMx’s unique platform of proprietary phage display libraries, Rapid Liquid Screening, and affinity maturation methods enables the fast delivery of recombinant antibodies with high specificity, affinity, and reproducibility that are optimized to perform a desired application. The company offers a full range of custom antibody discovery and development services for the research, diagnostic, and therapeutic marketplaces, including the new AxioMx Express custom antibody service which provides 5 week development of research use recombinant antibodies. For more information about AxioMx, please visit http://www.axiomxinc.com.

Contact info:
Chris McLeod
President and CEO
cmcleod(at)axiomxinc(dot)com
203-208-1918

For the original version on PRWeb visit: http://www.prweb.com/releases/AxioMx/SBIR/prweb13014210.htm